Literature DB >> 27031008

Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.

Fréderic Franconieri1, Nicolas Martin-Silva1, Hubert de Boysson1, Françoise Galateau-Salle2, Jean-François Emile3, Boris Bienvenu1, Achille Aouba1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27031008     DOI： 10.3109/0284186X.2015.1120885

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  5 in total

1.  Erdheim-Chester disease: 25-year history with early CNS involvement.

Authors:  C M Rice; C A Hall; P McCoubrie; S A Renowden; N Cohen; N J Scolding
Journal:  BMJ Case Rep       Date:  2016-10-04

Review 2.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

3.  Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Authors:  Fréderic Franconieri; Samuel Deshayes; Hubert de Boysson; Salim Trad; Nicolas Martin Silva; Benjamin Terrier; Boris Bienvenu; Françoise Galateau-Sallé; Jean-François Emile; Alison C Johnson; Achille Aouba
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

4.  Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.

Authors:  Xin-Xin Cao; Na Niu; Jian Sun; Hao Cai; Feng-Dan Wang; Yi-Ning Wang; Ming-Hui Duan; Dao-Bin Zhou; Jian Li
Journal:  Orphanet J Rare Dis       Date:  2019-01-10       Impact factor: 4.123

Review 5.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.